Accelerate Diagnostics, Inc. (LON: 0H8E)

Market Cap	22.77M
Revenue (ttm)	8.89M
Net Income (ttm)	-39.88M
Shares Out	n/a
EPS (ttm)	-1.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70
Average Volume	524
Open	1.090
Previous Close	1.145
Day's Range	1.090 - 1.090
52-Week Range	0.477 - 7.080
Beta	0.60
RSI	40.25
Earnings Date	Feb 27, 2025

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic sus...

• Industry: Medical - Specialties
• Sector: Healthcare
• Founded: 1982
• Employees: 134
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H8E

Financial Performance

In 2023, Accelerate Diagnostics's revenue was $12.06 million, a decrease of -5.43% compared to the previous year's $12.75 million. Losses were -$61.62 million, -1.40% less than in 2022.

Financial numbers in USD